AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19032138
Drug: CC (current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC (current care)
Trial: 17157780
Drug: Oxytrex (oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytrex (oxycodone + ultralow-dose naltrexone) bid
Trial: 10681282
Drug: Potato chips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potato chips containing 40 g of olestra per day
Trial: 3301923
Drug: Ketoconazole 2%
RxNorm normalized name: KETOCONAZOLE 2% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 2% cream once daily
Trial: 3301923
Drug: Ketoconazole 2%
RxNorm normalized name: KETOCONAZOLE 2% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 2% cream twice daily
Trial: 29534134
Drug: Tissue-level implants
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue-level implants restored with platform matching (control group)
Trial: 29534134
Drug: Bone-level implants
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-level implants restored with platform switching (test group)
Trial: 25201794
Drug: SSI reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSI reduction bundle (prohibition of razors, chlorhexidine-alcohol use, correct timing of prophylactic antibiotics)
Trial: 25201794
Drug: Correct timing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correct timing of preoperative prophylactic antibiotics
Trial: 19349870
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (lopinavir-ritonavir and 2 nucleosides)
Trial: 12399672
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (potent topical steroids + 20% azelaic acid cream)
Trial: 12399672
Drug: 20% azelaic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% azelaic acid cream monotherapy
Trial: 18653145
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of caloric restriction and physical exercise with pharmacological treatment
Trial: 7660761
Drug: 2‐h blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐h blood glucose value of 8.0 to 8.9 mmol/l
Trial: 7660761
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2‐h blood glucose value < 8.0 mmol/l)
Trial: 327948
Drug: Erbium 169
RxNorm normalized name: erbium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erbium 169 injection (+prednisolone acetate)
Trial: 327948
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection (+prednisolone acetate)
Trial: 31081712
Drug: Er;Cr:YSGG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er;Cr:YSGG laser treatment at 3.75 W power and 15 Hz frequency for 4 min
Trial: 31081712
Drug: Hydrofluoric (HF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrofluoric (HF) acid treatment
Trial: 31081712
Drug: L1S treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L1S treatment
Trial: 31081712
Drug: L2D treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L2D treatment
Trial: 31081712
Drug: L1D treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L1D treatment
Trial: 31081712
Drug: L2S treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L2S treatment
Trial: 19506377
Drug: Unsafe injecting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsafe injecting practices (syringe‐mediated drug sharing)
Trial: 16884321
Drug: FBT administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FBT administered as four 100 microg tablets simultaneously
Trial: 16884321
Drug: FBT administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FBT administered as one 400 microg tablet
Trial: 7571476
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg or 8 mg administered once a day)
Trial: 7571476
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of perindopril with hydrochlorothiazide
Trial: 7571476
Drug: Perindopril (monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (monotherapy and combination)
Trial: 2153736
Drug: Topical 15%
RxNorm normalized name: urea topical 15% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 15% idoxuridine in dimethyl sulfoxide
Trial: 2153736
Drug: 80% DMSO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80% DMSO control solution
Trial: 2153736
Drug: 2% DMSO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% DMSO control solution
Trial: 30326318
Drug: Biographical suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biographical suspension concept
Trial: 18319227
Drug: LPC infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPC infusions
Trial: 6487462
Drug: Cyclosidimine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosidimine 2.5 mg
Trial: 6487462
Drug: Cyclosidimine 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosidimine 5.0 mg
Trial: 6487462
Drug: Cyclosidimine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosidimine 7.5 mg
Trial: 26653112
Drug: 4000 IU
RxNorm normalized name: Cholecalciferol 4000 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 IU daily vitamin D3
Trial: 25347898
Drug: Meglumine antimoniate
RxNorm normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine antimoniate (conventional chemotherapy)
Trial: 22925288
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate (SH) solution (0.2% two-fold diluted MucoUp)
Trial: 18477422
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (L‐AMB)
Trial: 15807739
Drug: Isotretinoin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (1 mg/kg/day) + Vitamin E (800 IU/day)
Trial: 15807739
Drug: Isotretinoin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (1 mg/kg/day)
Trial: 2181312
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ivermectin (21.3 +/- 0.7 micrograms per kilogram; n = 13)
Trial: 2181312
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ivermectin (126.2 +/- 3.7 micrograms per kilogram; n = 13)
Trial: 2181312
Drug: Diethylcarbamazine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (6 mg per kilogram per day for 12 days preceded by 3 mg per kilogram for 1 day; n = 14)
Trial: 31624364
Drug: Hepcidin cutoff
RxNorm normalized name: Hepcidin-25
DrugBank: Hepcidin-25 (DB19226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepcidin cutoff <4.3 µg/L
Trial: 31624364
Drug: Baseline hemoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline hemoglobin >110 g/L
Trial: 31624364
Drug: Baseline hepcidin
RxNorm normalized name: Hepcidin-25
DrugBank: Hepcidin-25 (DB19226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline hepcidin >1.6 µg/L
Trial: 23305245
Drug: Trimethoprim 200
RxNorm normalized name: trimethoprim 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim 200 mg twice daily from day 5 to 10
Trial: 21557754
Drug: 0.3 g
RxNorm normalized name: sorbitol 0.3 GM Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g of dentifrice
Trial: 21557754
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g of dentifrice
Trial: 18461392
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of 0.1 ml 1% acetylcholine in group A
Trial: 9754775
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg plus Amoxicillin 1000 mg b.i.d (OA)
Trial: 9754775
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg and Placebo b.i.d (OP)
Trial: 7826832
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) - total dose of 1500 mg given over 3 days
Trial: 18454214
Drug: 10 mg.kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg.kg-1 ketamine 5%
Trial: 16418156
Drug: Nerve gliding
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve gliding exercises combined with conservative treatment
Trial: 16418156
Drug: Static volar
RxNorm normalized name: Polar Freeze
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static volar wrist splints and conservative treatment
Trial: 1607432
Drug: Chewable preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewable preparation containing chlorhexidine
Trial: 1607432
Drug: Xylitol control
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylitol control tablets
Trial: 3984878
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment) in patients with reperfusion
Trial: 2451713
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy followed by definitive treatment (arm A)
Trial: 24584605
Drug: MgCaCO3 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgCaCO3 (100 mg calcium, 85 mg magnesium per tablet)
Trial: 24584605
Drug: CaCO3 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaCO3 (200 mg calcium per tablet)
Trial: 24379009
Drug: Beef lunch
RxNorm normalized name: Beef
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beef lunch (3-oz, 3 times weekly for 16 weeks)
Trial: 24379009
Drug: Non-beef lunch
RxNorm normalized name: Beef
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-beef lunch (3-oz, 3 times weekly for 16 weeks)
Trial: 21257028
Drug: Malleable protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malleable protein matrix (MPM) 2 × 15 g/d
Trial: 18790543
Drug: Sulfotanshinone Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfotanshinone Sodium Injection (SSI) 60 mg combined with a loading dose of 300 mg aspirin and a maintenance dose of 100 mg of aspirin plus baseline therapy
Trial: 18790543
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg loading dose and 100 mg maintenance dose) plus baseline therapy
Trial: 16446121
Drug: Pregabalin as
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin as add-on therapy
Trial: 12232545
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of agomelatine
Trial: 7761292
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of behavior modification and mutual goal setting
Trial: 2175584
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg perindopril
Trial: 373990
Drug: Haloperidol 0.5
RxNorm normalized name: haloperidol 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 0.5 mg twice daily
Trial: 373990
Drug: Diazepam 2
RxNorm normalized name: diazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 2 mg three times daily
Trial: 31381147
Drug: Nintedanib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 200 mg twice daily on days 2‐21 every 3 weeks for up to 120 weeks combined with carboplatin and paclitaxel.
Trial: 29298726
Drug: BMAC-PRP injection
RxNorm normalized name: HEMOPHILUS B PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMAC-PRP injection
Trial: 25394847
Drug: Di'ao Xin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Di'ao Xin Xue Kang (XXK) capsule
Trial: 25394847
Drug: Compound Danshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Danshen (CDS) tablet
Trial: 22842953
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin 0.075 % 3 times daily for 6 weeks
Trial: 20884122
Drug: Praziquantel 75
RxNorm normalized name: METRONIDAZOLE 250 mg in 2 g / PRAZIQUANTEL 75 mg in 2 g TOPICAL POWDER [API General Cure]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 75 mg/kg
Trial: 18172274
Drug: Fenretinide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenretinide (200 mg/day orally for 12 months)
Trial: 10836286
Drug: Venlafaxine 37.5
RxNorm normalized name: venlafaxine 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 37.5 mg in the morning and evening, increased to 75 mg twice daily after 4 weeks
Trial: 10836286
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg in the morning and placebo in the evening, increased to 20 mg twice daily after 4 weeks
Trial: 8925479
Drug: Argon green
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argon green laser (AGL) treatment
Trial: 8925479
Drug: Krypton red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krypton red laser (KRL) treatment
Trial: 8925479
Drug: Both AGL
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both AGL and KRL treatments
Trial: 1806404
Drug: H1 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H1 antagonist (chlorpheniramine 4 mg)
Trial: 6761370
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg hydrochlorothiazide orally daily
Trial: 6761370
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg slow-release furosemide orally daily
Trial: 27842565
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (parenteral morphine at 0.1 mg/kg)
Trial: 8837185
Drug: Single-injection femoral
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection femoral 3-in-1 nerve block with 20 mL 0.5% bupivacaine with 1:200,000 epinephrine
Trial: 1360803
Drug: Alfentanil 5
RxNorm normalized name: alfentanil 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 5 micrograms/kg bolus followed by normal saline infusion
Trial: 1360803
Drug: Esmolol 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 500 micrograms/kg bolus followed by esmolol 300 micrograms/kg/min infusion
Trial: 1360803
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline bolus followed by normal saline infusion
Trial: 6386007
Drug: Nifedipine (NI)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (NI) 5, 10, 20 mg
Trial: 6386007
Drug: Acebutolol (AC)
DrugBank: Acebutolol (DB01193)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acebutolol (AC) 200 mg
Trial: 6386007
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NI (10 mg three times a day) and AC (200 mg three times a day)
Trial: 15752374
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg single-dose pitavastatin in Child-Pugh grade A
Trial: 15752374
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg single-dose pitavastatin in Child-Pugh grade B
Trial: 2971506
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral pills, progestogen‐only oral pills, vaginal ring
Trial: 20420959
Drug: Abdominal draw-in
RxNorm normalized name: Drawing Salve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal draw-in manoeuvre in combination with ankle dorsiflexion
Trial: 19045963
Drug: Coping-oriented couples
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coping-oriented couples therapy (COCT)
Trial: 15914517
Drug: Generic warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic warfarin (Apo-warfarin)
Trial: 12971525
Drug: HIV vaccine-related
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV vaccine-related research protocols
Trial: 1346963
Drug: Inhaled beta
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beta 2-agonists (higher doses)
Trial: 1346963
Drug: Regular use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular use of inhaled beta 2-agonists
Trial: 1346963
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (additional therapy)
Trial: 1346963
Drug: Novel longer-acting
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel longer-acting inhaled beta 2-agonists (salmeterol and formoterol)
Trial: 6497569
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg/kg twice a day for two weeks)
Trial: 29488154
Drug: Fasiglifam (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasiglifam (25 mg oral dose)
Trial: 25584315
Drug: PRF gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRF gel (experimental group I)
Trial: 25584315
Drug: PRF gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRF gel and PRF membrane (experimental group II)
Trial: 22449332
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with darbepoetin and G-CSF (n = 41), G-CSF was treated for 3 days at a dose of 10 μg/kg/day, plus a single intravenous injection of 4.5 μg/kg of darbepoetin after coronary angioplasty.
Trial: 22449332
Drug: G-CSF alone
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF alone (n = 19), treated for 3 days at a dose of 10 μg/kg/day.
Trial: 20807664
Drug: Edoxaban (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (60 mg, twice-daily, 7 doses)
Trial: 20807664
Drug: Dalteparin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (5000 IU, once-daily, 4 doses)
Trial: 20807664
Drug: Ximelagatran (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran (24 mg, twice-daily, 7 doses)
Trial: 15800321
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by chemoradiotherapy (40 Gy) followed by surgery (arm A)
Trial: 15800321
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by chemoradiotherapy (at least 65 Gy) without surgery (arm B)
Trial: 8594122
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) codeine (277 ± 77 mg daily, given every 12 hr)
Trial: 1706015
Drug: Diuretic (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic (25 mg hydrochlorothiazide and 50 mg triamterene)
Trial: 6785336
Drug: Long-term chrysotherapy
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term chrysotherapy (gold therapy)
Trial: 29183324
Drug: Bar (565
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bar (565 kJ, 7.5 g EAAs, 40% L-leucine)
Trial: 29183324
Drug: Gel (477
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel (477 kJ, 7.5 g EAAs, 40% L-leucine)
Trial: 17032712
Drug: Calcitriol 0.25
RxNorm normalized name: CALCITRIOL 0.25MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 0.25 mug twice a day
Trial: 8589000
Drug: G‐CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (5 micrograms/kg/day)
Trial: 31410778
Drug: Experimental hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental hyperbaric oxygen therapy
Trial: 22779693
Drug: Alosetron 0.5
RxNorm normalized name: alosetron 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron 0.5 mg QD
Trial: 22779693
Drug: Alosetron 1
RxNorm normalized name: alosetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron 1 mg BID
Trial: 22779693
Drug: Alosetron (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron (all doses)